Premium
Serum Hormone Levels in Patients with Malignant Testicular Germ Cell Tumours without Clinical and/or Radiological Sings of Tumour
Author(s) -
FOSSÅ S. D.,
KLEPP O.,
AAKVAAG A.
Publication year - 1980
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1980.tb02946.x
Subject(s) - radiological weapon , hormone , medicine , germ cell , pathology , seminoma , oncology , biology , radiology , chemotherapy , biochemistry , gene
Summary— In patients treated for malignant testicular tumours wihout clinical and/or radiological signs of tumour, the following serum hormone levels were found: In 15% of the patients there was a slight to moderate rise in luteinising hormone (LH) levels (up to 6 μg/1) due to increased pituitary gonadotrophin production; this was particularly evident soon after radiotherapy/chemotheraphy. In 50% of the patients there was a slight to marked increase in follicle stimulating hormone (FSH) levels (up to 11 μg/1), especially after radiotherapy/chemotherapy. Serum testosterone levels were in the low range (up to 20 nmol/l) in the majority of the hemicastrated patients regardless of previous treatment. A slight to moderate rise in serum oestradiol‐17β and serum prolactin levels was noted. During combination chemotherapy with vincristine, Adriamycin D, cyclophosphamide, actinomycin D and medroxyprogesterone acetate the serum testosterone levels were extremely low (below 6 nmol/l) with LH and FSH levels within the normal range. The decrease in testosterone levels was reversible after completion of the combination chemotheraphy.